1. Gastrointestinal Motility Enhancement: Prucalopride succinate is a selective serotonin 5-HT4 receptor agonist. By stimulating these receptors in the gastrointestinal tract, it enhances the coordinated movement of the intestines, promoting effective peristalsis and alleviating symptoms of chronic constipation.
2. Increased Bowel Movements: This drug significantly increases the frequency of spontaneous bowel movements, providing relief for patients with severe chronic constipation who do not respond adequately to conventional laxatives.
3. Improvement of Colonic Transit: Prucalopride effectively accelerates colonic transit time. The primary mechanism is through enhancing contraction waves in the colon, aiding in the movement of stool, thereby leading to a reduction in colonic transit times.
4. Safety Profile: Prucalopride has a good safety profile, with the most commonly reported side effects being headache and gastrointestinal symptoms such as abdominal pain, diarrhea, and nausea. It is typically well-tolerated by the majority of users.
5. Selective Action: Its high selectivity for the 5-HT4 receptor means that it has fewer cardiovascular and gastrointestinal side effects compared to earlier non-selective prokinetic drugs, making it safer for long-term use.
